A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

February 18, 2025

Study Completion Date

February 18, 2025

Conditions

Healthy

Interventions

DRUG

Efinopegdutide

Subcutaneous injectable solution

DRUG

Placebo

Subcutaneous injectable solution

DRUG

Acetaminophen

Oral solution

Trial Locations (1)

QPS-MRA, LLC (Site 0001), South Miami

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06701305 - A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015) | Biotech Hunter | Biotech Hunter